BMY Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

9 · Strong Momentum 5.0 · Neutral Watch 16y streak Reports in 11d

59.75

-1.35%

About the company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Website Annual reports (10-K)

4.22%

55.51%

2.52

122.1B

13.16

4.54

59.64

52-week range

59.8

low 42.5 high 68.6

Dividend deep dive

Bristol-Myers Squibb Company, a healthcare firm in the Drug Manufacturers - General sector, currently offers a dividend yield of 4.01%. This yield is positioned within its 5-year historical band, slightly above its 5-year average yield of 3.89% and below its 5-year high of 4.89%. The company holds a strong overall rating score of 9.0. Its stock exhibits robust price momentum with a score of 8.0 and a favorable value score of 8.3, suggesting it is neither excessively cheap nor rich based on current metrics.

Dividend history

Bristol-Myers Squibb has a consistent record of dividend increases, marking 16 consecutive years and classifying it as a CCC Contender. Over the past three years, the dividend has grown at a compound annual growth rate (CAGR) of 4.71%. Its five-year dividend CAGR is 6.62%, indicating a dividend doubling time of approximately 10.9 years. Recent annual dividend payments include $2.28 in 2023 and $2.40 in 2024, with a projected $2.48 for 2025, demonstrating ongoing growth from $1.44 in 2014.

Dividend safety

The dividend coverage for Bristol-Myers Squibb shows a payout ratio of 55.51% based on EPS. The company's leverage is elevated, with a debt-to-equity ratio of 230.97%.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

Try a sample portfolio Sign up free

AI-generated from Quantic's dividend data · Updated 28 Sep 2026 · Information, not financial advice.